ArticleHematology reports2025

Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A Patients.

Maria Choví-Trull et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.